Predictability of hematopoietic stem cell transplantation rates
- 1 December 2007
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 92 (12) , 1679-1686
- https://doi.org/10.3324/haematol.11260
Abstract
Background and Objectives Hematopoietic stem cell transplantation (HSCT) is a complex and expensive procedure. Trends in the use of this procedure have appeared erratic in the past. Information on future needs is essential for health care administrators. Design and Methods We analyzed the evolution of transplant rates, e.g. numbers of transplants per 10 million inhabitants, in Europe from 1990 to 2004 for all major disease categories and used Gross National Income (GNI) per capita, team density (numbers of teams per 10 million inhabitants) and team distribution (numbers of teams per 10,000 km2) to measure the impact of economic factors in participating countries. Trends were compared by regression analyses, and countries were grouped by World Bank definitions into high, middle and low income categories. Results Transplant rates increased over time with nearly linear trends, in clear association with GNI per capita (R2=0.72), and distinct by World Bank category within a narrow window of variation for both autologous HSCT (R2=0.95, 0.98 and 0.94 for high, middle and low income categories, respectively) and allogeneic HSCT (R2=0.99, 0.96 and 0.95 for high, middle and low income categories, respectively) when breast cancer (autologous) and chronic myeloid leukemia (allogeneic) were excluded. Team density (R2=0.72) and team distribution (R2=0.51) were also associated with transplant rates. Interpretation and Conclusions Transplant rates for HSCT in Europe are highly predictable. They are primarily influenced by GNI per capita. The absence of saturation and a nearly linear trend indicate that infrastructure lags behind medical needs. Isolated changes in single disease entities can easily be recognized.Keywords
This publication has 9 references indexed in Scilit:
- Do affluent societies have the only options for the best therapy?Leukemia, 2007
- Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe—Impact of cost considerationsLeukemia, 2007
- Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetBlood, 2006
- EBMT activity survey 2004 and changes in disease indication over the past 15 yearsBone Marrow Transplantation, 2006
- Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in EuropeBone Marrow Transplantation, 2006
- The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter studyBone Marrow Transplantation, 2005
- Blood and marrow transplantation compensation: Perspective in payer and provider relationsTransplantation and Cellular Therapy, 2004
- Hematopoietic stem cell transplantation for hematological malignancies in EuropeLeukemia, 2003
- Current trends in hematopoietic stem cell transplantation in EuropeBlood, 2002